The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

By Bhanvi Satija and Christy Santhosh (Reuters) -Talks with the Trump administration about lowering U.S. drug prices have so ...

The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year ...

UnitedHealth weighs $1B deal for Banmedica - report. Chime Financial IPO demand blows past share supply ahead of pricing. U.S ...

Sildenafil citrate during labor did not improve perinatal outcomes potentially related to intrapartum hypoxia despite ...

Currently, Merck stock shows potential for another collar setup, with defined risk and reward, though I haven't executed a ...

Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...

NMPA’s Center for Drug Evaluation accepted Merck KGaA’s application for marketing authorization of pimicotinib as a Class 1 ...

Merck won FDA approval for a shot that protects against RSV, the most common cause of hospitalization among infants ...

Pfizer CEO Albert Bourla has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing that his ...

As President Donald Trump vows to bridge the drug pricing gap between the U.S. and other developed countries with his “most ...

The green light in the US is the first worldwide for Enflonsia ( clesrovimab) and makes the long-acting antibody the first ...